AI Article Synopsis
- - The study investigates the prevalence of laryngopharyngeal reflux disease (LPRD) in patients with type 2 diabetes mellitus (T2DM) and its relationship with glycemic control, disease duration, and neuropathy.
- - It found that 22% of T2DM patients showed signs of LPRD, slightly higher than the 9.1% in the control group; however, the difference was not statistically significant.
- - The most notable symptoms in T2DM patients included increased throat clearing and a sensation of a lump in the throat, with LPRD being correlated to the presence of neuropathy, despite no strong overall correlation with other demographic factors.
Article Abstract
Objective: To study the prevalence of laryngopharyngeal reflux disease (LPRD) in patients with type 2 diabetes mellitus (T2DM) and report the correlation between LPRD and glycemic control, duration of the disease, and presence of neuropathy.
Materials And Methods: This is a cross-sectional study of 100 patients with T2DM and 33 controls matched according to age and gender. The reflux symptom index (RSI) was used to assess the presence of LPRD. A score greater than 10 was considered diagnostic of LPRD.
Results: Twenty-two percent of patients with T2DM had RSI above 10 versus 9.1% of controls. The difference was not statistically different (P value of 0.100). The average score of all symptoms of LPRD was higher in the diabetic group compared with the control group. There was a significant increase in the average score of "throat clearing" and "lump sensation in throat," with a borderline significant increase in "annoying cough" in patients with diabetes versus controls (respective P values of 0.03, 0.025, and 0.066). There was no correlation between LPRD and any of the demographic variables except neuropathy.
Conclusion: Patients with T2DM are more likely to have LPRD compared with controls. However, the prevalence of LPRD is not significantly higher in diabetic patients compared with controls. When present, LPRD correlates with neuropathy.
Level Of Evidence: 2c.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvoice.2012.07.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Imperial College London, London, United Kingdom; Division of Neurology, Department of Brain Sciences, Imperial College London, United Kingdom, London, London, United Kingdom.
Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue licensed for the treatment of type 2 diabetes mellitus (T2DM). Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells.
Method: This is a multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild to moderate Alzheimer's dementia, conducted at several centres in the UK.
Drug Development.
Alzheimers Dement
December 2024
National Institute on Aging, NIH, Baltimore, MD, USA.
Background: Epidemiological studies report an elevated risk of neurodegenerative disorders, particularly Parkinson's disease (PD), in patients with type 2 diabetes mellitus (T2DM) that is mitigated in those prescribed incretin mimetics or dipeptidyl peptidase 4 inhibitors (DPP-4Is). Incretin mimetic repurposing appears promising in human PD and Alzheimer's disease (AD) clinical trials. DPP-4Is are yet to be evaluated in PD or AD human studies.
View Article and Find Full Text PDFIntermittent Use of Flash Glucose Monitoring Improves Glycemic Control in Chinese Older Patients with Type 2 Diabetes Mellitus.
Diabetes Metab Syndr Obes
January 2025
Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210012, People's Republic of China.
Objective: To explore the efficacy and safety of intermittent use of flash glucose monitoring (FGM) for improving glycemic control in Chinese elderly patients with type 2 diabetes mellitus (T2DM).
Methods: This is a prospective observational study involving patients with T2DM aged ≥60 years. The study period spans 12 weeks, with participants wearing FGM at weeks 0, 5, and 10.
Association Between Maximum Lifetime Body Mass Index and Nailfold Capillary Changes in Patients With Type 2 Diabetes Mellitus.
Cureus
December 2024
Department of Mathematical Health Science, Graduate School of Medicine, Osaka University, Osaka, JPN.
Objective: Microvascular changes, such as crossing nailfold capillaries, could be crucial for linking maximum lifetime body mass index (BMI) and microvascular complications in patients with type 2 diabetes mellitus (T2DM). However, the relationship between maximum lifetime BMI and microvascular changes remains elusive. This study aimed to elucidate the relationship between maximum lifetime BMI and the percentage of crossing nailfold capillaries among patients with T2DM.
View Article and Find Full Text PDFSemaglutide vs. dulaglutide for glycemic and weight control in patients with type 2 diabetes mellitus: A systematic review and meta‑analysis.
Biomed Rep
March 2025
Department of Endocrinology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, P.R. China.
The present systematic review and meta-analysis aimed to evaluate the effectiveness of semaglutide and dulaglutide for glycemic control and weight loss in patients with type 2 diabetes mellitus (T2DM). A thorough literature search was conducted using several databases from inception until the end of July 2024. The primary outcome was the difference in glycated hemoglobin levels from the initial measurement between the groups.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!